Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors - A novel antiproliferative/antiangiogenic strategy in thyroid cancer

Langenbeck's Archives of Surgery

Volumn 391, Issue 6, 2006, Pages 589-596

  Hoffmann, S ^a   Glaser S ^a   Wunderlich, A ^a   Lingelbach, S ^a   Dietrich, C ^a   Burchert, A ^a   Muller H ^a   Rothmund, M ^a   Zielke, A ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Angiogenesis; EGF; EGF R; Thyroid cancer; Tyrosine kinase inhibitor; VEGF; VEGF R

Indexed keywords

ENDOTHELIAL CELL GROWTH FACTOR; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR; VANDETANIB; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; THYROID CANCER; WESTERN BLOTTING;

CARCINOMA; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; PIPERIDINES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; THYROID NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33750453810     PISSN: 14352443     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00423-006-0104-y     Document Type: Article

References (46)

1. Caron NR, Clark OH (2004) Well differentiated thyroid cancer. Scand J Surg 93:261-267
2. Diehl S, Umbricht CB, Dackiw AP, Zeiger MA (2005) Modern approaches to age-old questions about thyroid tumors. Thyroid 15:575-582
3. Ain KB (1999) Anaplastic thyroid carcinoma: a therapeutic challenge. Semin Surg Oncol 16:64-69
4. McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, van Heerden JA, Goellner JR (2001) Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 130:1028-1034
5. Pasieka JL (2003) Anaplastic thyroid cancer. Curr Opin Oncol 15:78-83
6. Folkmann J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6
7. Hanahan D, Folkmann J (1996) Patterns and emerging mechanisms of the angiogenetic switch during tumorigenesis. Cell 86:353-364
8. Ramsden JD (2000) Angiogenesis in the thyroid gland. J Endocrinol 166:475-480
9. Lin JD, Chao TC (2005) Vascular endothelial growth factor in thyroid cancers. Cancer Biother Radiopharm 20:648-661
10. Siironen P, Louhimo J, Nordling S, Ristimaki A, Maenpaa H, Haapiainen R, Haglund C (2005) Prognostic factors in papillary thyroid cancer: an evaluation of 601 consecutive patients. Tumour Biol 26:57-64
11. Kebebew E, Peng M, Reiff E, Duh QY, Clark OH, McMillan A (2005) Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms. Surgery 138:1102-1109
12. Kim DS, Franklyn JA, Stratford AL, Boelaert K, Watkinson JC, Eggo MC, McCabe CJ (2006) Pituitary tumor transforming gene (PTTG) regulates multiple downstream angiogenic genes in thyroid cancer. J Clin Endocrinol Metab 91:1119-1128
13. Summy JM, Trevino JG, Baker CH, Gallick GE (2005) c-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and p38 MAPK. Pancreas 31:263-274
14. Bergstrohm JD, Westermark B, Heldin NE (2000) EGF receptor signaling activated met in human anaplastic thyroid carcinoma cells. Exp Cell Res 259:293-299
15. Frauman AG, Moses AC (1990) Oncogenes and growth factors in thyroid carcinogenesis. Endocrinol Metab Clin N Am 19:479-493
16. Akslen LA, Myking AO, Salvesen H, Varhaug JE (1993) Prognostic impact of EGF-receptor in papillary thyroid carcinoma. Br J Cancer 68:808-812
17. Duh QY, Gum ET, Gerend PL, Raper SE, Clark OH (1990) Epidermal growth factor receptor and adenylate cyclase activity in human thyroid tissue. World J Surg 14:410-418
18. Hoelting T, Siperstein AE, Clark OH, Duh QY (1994) Epidermal growth factor enhances proliferation, migration, and invasion of follicular and papillary thyroid cancer in vitro and in vivo. J Clin Endocrinol Metab 79:401-408
19. Hoelting T, Zielke A, Siperstein AE, Clark OH, Duh QY (1994) Aberrations of growth factor control in metastatic follicular thyroid cancer in vitro. Clin Exp Metastasis 12:315-323
20. Hoffmann S, Hofbauer LC, Scharrenbach V, Wunderlich A, Hassan I, Lingelbach S, Zielke A (2004) TSH-induced production of VEGF in thyroid cancer cells in vitro: evaluation of TSH-signal transduction and of angiogenesis-stimulating growth factors. J Clin Endocrinol Metab 89:6139-6145
21. Gabler B, Aicher T, Heiss P, Senekowitsch-Schmidtke R (1997) Growth inhibition of human papillary thyroid carcinoma cells and multicellular spheroids by anti-EGF-receptor antibody. Anticancer Res 17:3157-3159
22. Ciardiello F (2005) Epidermal growth factor receptor inhibitors in cancer treatment. Fut Oncol 1:221-234
23. Siegel-Lakhai WS, Beijnen JH, Schellens JH (2005) Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Oncologist 10:579-589
24. Jones HE, Gee JM, Taylor KM, Barrow D, Williams HD, Rubini M, Nicholson RI (2005) Development of strategies for the use of anti-growth factor treatments. Endocr Relat Cancer 12(Suppl 1):S173-S182
25. Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, Kim S, Zhou G, Mandal M, Bekele BN, Holsinger FC, Sherman SI, Yeung SC, El-Naggar AK, Myers JN (2004) Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res 10:8594-8602
26. Ryan AJ, Wedge SR (2005) ZD6474 - a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer 92(Suppl 1):S6-S13
27. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62:4645-4655
28. Heldin NE, Westermark B (1991) The molecular biology of the human anaplastic thyroid carcinoma cell. Thyroidology 3:127-131
29. Ishizaka Y, Ushijima T, Sugimura T, Nagao M (1990) cDNA cloning and characterization of ret activated in a human papillary thyroid carcinoma cell line. Biochem Biophys Res Commun 168:402-408
30. Middeke M, Hoffmann S, Hassan I, Wunderlich A, Hofbauer LC, Zielke A (2002) In vitro and in vivo angiogenesis in PC12 pheochromocytoma cells is mediated by vascular endothelial growth factor. Exp Clin Endocrinol Diabetes 110:386-392
31. Caponigro F, Formato R, Caraglia M, Normanno N, Iaffaioli RV (2005) Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors. Curr Opin Oncol 17:212-217
32. Bauer AJ, Terrell R, Doniparthi NK, Patel A, Tuttle RM, Saji M, Ringel MD, Francis GL (2002) Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. Thyroid 12:953-961
33. Bauer AJ, Patel A, Terrell R, Doniparthi K, Saji M, Ringel M, Tuttle RM, Francis GL (2003) Systemic administration of vascular endothelial growth factor monoclonal antibody reduces the growth of papillary thyroid carcinoma in a nude mouse model. Ann Clin Lab Sci 33:192-199
34. Schoenberger J, Grimm D, Kossmehl P, Infanger M, Kurth E, Eilles C (2004) Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study. Endocrinology 145:1031-1038
35. Younes MN, Yigitbasi OG, Park YW, Kim SJ, Jasser SA, Hawthorne VS, Yazici YD, Mandal M, Bekele BN, Bucana CD, Fidler IJ, Myers JN (2005) Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation. Cancer Res 65:4716-4727
36. Konturek A, Barczynski M, Cichon S, Pituch-Noworolska A, Jonkisz J, Cichon W (2005) Significance of vascular endothelial growth factor and epidermal growth factor in development of papillary thyroid cancer. Am J Infect Control 390:216-221
37. Vieira JM, Santos SC, Espadinha C, Correia I, Vag T, Casalou C, Cavaco BM, Catarino AL, Dias S, Leite V (2005) Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop. Eur J Endocrinol 153:701-709
38. Kim CS, Vasko VV, Kato Y, Kruhlak M, Saji M, Cheng SY, Ringel MD (2005) AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma. Endocrinology 146:4456-4463
39. Nobuhara Y, Onoda N, Yamashita Y, Yamasaki M, Ogisawa K, Takashima T, Ishikawa T, Hirakawa K (2005) Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. Br J Cancer 92:1110-1116
40. Taguchi F, Koh Y, Koizumi F, Tamura T, Saijo N, Nishio K (2004) Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models. Cancer Sci 95:984-989
41. Moasser MM, Basso A, Averbuch SD, Rosen N (2001) The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61:7184-7188
42. Ciardiello F, Caputo R, Damiano V, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, Tortora G (2003) Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 9:1546-1556
43. Hoffmann S, Wunderlich A, Celik I, Maschuw K, Hassan Y, Lingelbach S, Zielke A (2006) Paneling human thyroid cancer cell lines for candidate proteins for targeted anti-angiogenic therapy. J Cell Biochem 98:954-965
44. Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD, Maity A (2006) EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res 66:3197-3204
45. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M (2002) ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62:7284-7290
46. Ishizaka Y, Ushijima T, Sugimura T, Nagao M (1990) cDNA cloning and characterization of ret activated in a human papillary thyroid carcinoma cell line. Biochem Biophys Res Commun 168:402-408